Results from a randomized phase II study indicate that adding the experimental antibody IMAB362, which targets the tight junction protein claudin18.2, to standard chemotherapy is more effective than chemotherapy alone in previously untreated patients with advanced gastric cancer. IMAB362 extended progression-free and overall survival by 3.1 months and 4.8 months, respectively.
from Cancer via ola Kala on Inoreader http://ift.tt/2arS871
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου